Hostname: page-component-7479d7b7d-m9pkr Total loading time: 0 Render date: 2024-07-12T22:25:17.205Z Has data issue: false hasContentIssue false

Selective estrogen receptor modulators (SERMs) in postmenopausal women's health

Published online by Cambridge University Press:  13 February 2001

DW Purdie
Affiliation:
Centre for Metabolic Bone Disease, University of Hull, Hull Royal Infirmary, Hull, UK
P Albertazzi
Affiliation:
Centre for Metabolic Bone Disease, University of Hull, Hull Royal Infirmary, Hull, UK

Abstract

Over the past ten years mortality for breast cancer in the UK has been falling. The decrement has been more substantial in the 20 to 69 age group, which has seen a 22% decrease, while in the 70 to 79 age group the decrease has been milder at 12%. The incidence of the disease, however, is increasing and many women have a relative or friend with a disease that they perceive to be extremely mutilating. Fear of breast cancer is such among women that it is mistakenly viewed as the most common cause of death in females. Postmenopausal hormone replacement therapy (HRT) has many benefits and is particularly effective in the prevention of osteoporosis. But, to obtain this effect, HRT has to be continued for many years and long-term treatment has been shown to slightly increase the risk of breast cancer. This fact forcefully stimulated the imagination of both press and public alike.

Type
Research Article
Copyright
© 2000 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)